Identification

Name
Ergoloid mesylate
Accession Number
DB01049  (APRD00711, DB01287)
Type
Small Molecule
Groups
Approved
Description

Ergoloid mesylate is a dihydrogenated ergot (Claviceps purpurea) derivative alkaloid used as a vasodilator agent. Ergoloid Mesylate is the only vasodilator that has shown mild benefits in the treatment of vascular dementia. Ergoloid Mesylate is a mixture of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. It has been proposed to be a neuroprotective agent. The mechanism of its therapeutic actions is not clear.

Synonyms
  • co-dergocrine mesilate
  • co-dergocrine mesylate
  • co-dergocrine methanesulfonate
  • codergocrine mesilate
  • codergocrine mesylate
  • codergocrine methanesulfonate
  • Dihydroergotoxine Mesilate
  • Dihydroergotoxine Mesylate
  • dihydroergotoxine methanesulfonate
  • Dihydroergotoxine Methanesulfonate
  • dihydroergotoxine methanesulfonates
  • dihydroergotoxine monomethanesulfonate
  • dihydrogenated ergot alkaloids
  • Ergoloid Mesylates
  • ergoloid methanesulfonate
  • ergoloid methanesulfonates
  • hydrogenated ergot alkaloids
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hydergine Tablets, 1mgTablet1 mgOralSterimax Inc1968-12-31Not applicableCanada
International/Other Brands
Alkergot / Circanol / Deapril / Gerimal / Hydergine / Hydergine LC
Categories
UNII
X3S33EX3KW
CAS number
8067-24-1
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

For use as an adjunct therapy for patients with dementia.

Structured Indications
Pharmacodynamics

Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.

Mechanism of action

Ergoloid mesylates act centrally, decreasing vascular tone and slowing the heart rate, and acts peripherally to block alpha-receptors. One other possible mechanism is the effect of ergoloid mesylates on neuronal cell metabolism, resulting in improved oxygen uptake and cerebral metabolism, thereby normalizing depressed neurotransmitter levels.

TargetActionsOrganism
AAlpha-2 adrenergic receptors
antagonist
Human
AAlpha-1 adrenergic receptors
antagonist
Human
ASolute carrier organic anion transporter family member 2B1
inhibitor
Human
USerotonin Receptors
antagonist
Human
UD(1A) dopamine receptor
antagonist
agonist
Human
UD(2) dopamine receptor
antagonist
agonist
Human
UGABA-A receptor (anion channel)
agonist
Human
Absorption

Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.

Volume of distribution
Not Available
Protein binding

98-99%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

3.5 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AmiodaroneThe metabolism of Ergoloid mesylate can be decreased when combined with Amiodarone.Approved, Investigational
AprepitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Ergoloid mesylate can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Ergoloid mesylate can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Atorvastatin.Approved
BoceprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Ergoloid mesylate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ergoloid mesylate.Approved
CarbamazepineThe metabolism of Ergoloid mesylate can be increased when combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ergoloid mesylate.Withdrawn
ClarithromycinThe metabolism of Ergoloid mesylate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ergoloid mesylate can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Ergoloid mesylate can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Ergoloid mesylate.Approved, Investigational
CrizotinibThe metabolism of Ergoloid mesylate can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Ergoloid mesylate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Ergoloid mesylate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ergoloid mesylate can be decreased when combined with Delavirdine.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ergoloid mesylate.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ergoloid mesylate.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Ergoloid mesylate.Experimental
DihydroergotamineThe metabolism of Ergoloid mesylate can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Ergoloid mesylate can be decreased when combined with Diltiazem.Approved
DoxycyclineThe metabolism of Ergoloid mesylate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Ergoloid mesylate can be decreased when combined with Dronedarone.Approved
EnzalutamideThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Ergoloid mesylate can be decreased when combined with Erythromycin.Approved, Vet Approved
FluconazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Fluconazole.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Ergoloid mesylate.Approved
FluvoxamineThe metabolism of Ergoloid mesylate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ergoloid mesylate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Ergoloid mesylate can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fusidic Acid.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Ergoloid mesylate.Approved
IdelalisibThe metabolism of Ergoloid mesylate can be decreased when combined with Idelalisib.Approved
ImatinibThe metabolism of Ergoloid mesylate can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Ergoloid mesylate can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Ergoloid mesylate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Ergoloid mesylate can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ketoconazole.Approved, Investigational
LopinavirThe metabolism of Ergoloid mesylate can be decreased when combined with Lopinavir.Approved
LorpiprazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Ergoloid mesylate can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ergoloid mesylate can be increased when combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Ergoloid mesylate.Illicit, Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Ergoloid mesylate.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ergoloid mesylate.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Ergoloid mesylate.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Ergoloid mesylate.Experimental
MifepristoneThe serum concentration of Ergoloid mesylate can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Mitotane.Approved
NefazodoneThe metabolism of Ergoloid mesylate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ergoloid mesylate can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ergoloid mesylate can be increased when combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Ergoloid mesylate.Approved, Investigational
NilotinibThe metabolism of Ergoloid mesylate can be decreased when combined with Nilotinib.Approved, Investigational
NitroglycerinThe bioavailability of Ergoloid mesylate can be increased when combined with Nitroglycerin.Approved, Investigational
OlaparibThe metabolism of Ergoloid mesylate can be decreased when combined with Olaparib.Approved
OsimertinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Osimertinib.Approved
PalbociclibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe metabolism of Ergoloid mesylate can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Ergoloid mesylate can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Ergoloid mesylate can be increased when combined with Phenytoin.Approved, Vet Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ergoloid mesylate.Approved
PosaconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ergoloid mesylate.Approved
PrimidoneThe metabolism of Ergoloid mesylate can be increased when combined with Primidone.Approved, Vet Approved
RanolazineThe metabolism of Ergoloid mesylate can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Ergoloid mesylate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ergoloid mesylate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ergoloid mesylate can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Ergoloid mesylate.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ergoloid mesylate.Approved
RucaparibThe metabolism of Ergoloid mesylate can be decreased when combined with Rucaparib.Approved, Investigational
SaquinavirThe metabolism of Ergoloid mesylate can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Sarilumab.Approved
SildenafilThe metabolism of Ergoloid mesylate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ergoloid mesylate.Approved
St. John's WortThe serum concentration of Ergoloid mesylate can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Ergoloid mesylate can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Ergoloid mesylate can be decreased when combined with Telithromycin.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Ergoloid mesylate.Experimental
TiclopidineThe metabolism of Ergoloid mesylate can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Tocilizumab.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ergoloid mesylate.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Ergoloid mesylate.Approved, Investigational, Nutraceutical
VemurafenibThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Ergoloid mesylate can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Ergoloid mesylate can be decreased when combined with Verapamil.Approved
VoriconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Ergoloid mesylate can be decreased when combined with Ziprasidone.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D02268
KEGG Compound
C14055
PubChem Substance
46505963
ChemSpider
60600935
ChEBI
34706
Therapeutic Targets Database
DAP000901
PharmGKB
PA164752439
Wikipedia
Ergoloid
AHFS Codes
  • 12:16.00 — Sympatholytic (Adrenergic Blocking) Agents
MSDS
Download (72.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentDementia, Vascular1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral1 mg
Prices
Unit descriptionCostUnit
Ergoloid mesylates powder87.5USD g
Ergoloid mesylates 1 mg tablet1.3USD tablet
Hydergine 1 mg Tablet1.1USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.8Not Available
Predicted Properties
Not Available
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8284
Blood Brain Barrier-0.9494
Caco-2 permeable-0.6447
P-glycoprotein substrateSubstrate0.6838
P-glycoprotein inhibitor IInhibitor0.6581
P-glycoprotein inhibitor IINon-inhibitor0.8001
Renal organic cation transporterNon-inhibitor0.8838
CYP450 2C9 substrateNon-substrate0.75
CYP450 2D6 substrateNon-substrate0.7966
CYP450 3A4 substrateSubstrate0.6681
CYP450 1A2 substrateNon-inhibitor0.7702
CYP450 2C9 inhibitorNon-inhibitor0.7072
CYP450 2D6 inhibitorNon-inhibitor0.9221
CYP450 2C19 inhibitorNon-inhibitor0.6493
CYP450 3A4 inhibitorNon-inhibitor0.7973
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8464
Ames testNon AMES toxic0.6324
CarcinogenicityNon-carcinogens0.6535
BiodegradationNot ready biodegradable0.9321
Rat acute toxicity2.5438 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8821
hERG inhibition (predictor II)Inhibitor0.5783
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...

Components:
References
  1. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Lu WJ, Huang JD, Lai ML: The effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine. J Clin Pharmacol. 2006 Jun;46(6):628-34. [PubMed:16707409]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...

Components:
References
  1. Flynn BL, Ranno AE: Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. [PubMed:10084415]
  2. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188]
  3. Wadworth AN, Chrisp P: Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging. 1992 May-Jun;2(3):153-73. [PubMed:1606351]
  4. Korneyev AY, Cincotta AH: Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. 1996;58(12):241-8. [PubMed:8786706]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Flynn BL, Ranno AE: Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. [PubMed:10084415]
  2. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188]
  3. Wadworth AN, Chrisp P: Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging. 1992 May-Jun;2(3):153-73. [PubMed:1606351]
  4. Korneyev AY, Cincotta AH: Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. 1996;58(12):241-8. [PubMed:8786706]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Tvrdeic A, Pericic D: Effect of ergot alkaloids on 3H-flunitrazepam binding to mouse brain GABAA receptors. Coll Antropol. 2003;27 Suppl 1:175-82. [PubMed:12955907]
  2. Tvrdeic A, Pericic D: Dihydrogenated ergot compounds bind with high affinity to GABAA receptor-associated Cl- ionophore. Eur J Pharmacol. 1991 Sep 4;202(1):109-11. [PubMed:1664802]
  3. Korneyev AY, Cincotta AH: Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. 1996;58(12):241-8. [PubMed:8786706]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Althaus M, Retzow A, Castell JV, Gomez-Lechon MJ, Amalou Z, Rose T, Appel K: In vitro identification of the cytochrome P450 isoform responsible for the metabolism of alpha-dihydroergocryptine. Xenobiotica. 2000 Nov;30(11):1033-45. [PubMed:11197065]

Drug created on June 13, 2005 07:24 / Updated on January 14, 2018 10:04